Skip to main content
PMC home page
Clinical Microbiology Reviews logoLink to Clinical Microbiology Reviews
. 1993 Oct;6(4):367–381. doi: 10.1128/cmr.6.4.367

Antifungal susceptibility testing.

J H Rex 1, M A Pfaller 1, M G Rinaldi 1, A Polak 1, J N Galgiani 1
PMCID: PMC358294  PMID: 8269392

Abstract

Unlike antibacterial susceptibility testing, reliable antifungal susceptibility testing is still largely in its infancy. Many methods have been described, but they produce widely discrepant results unless such factors as pH, inoculum size, medium formulation, incubation time, and incubation temperature are carefully controlled. Even when laboratories agree upon a common method, interlaboratory agreement may be poor. As a result of numerous collaborative projects carried out both independently and under the aegis of the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards, the effects of varying these factors have been extensively studied and a standard method which minimizes interlaboratory variability during the testing of Candida spp. and Cryptococcus neoformans has been proposed. This review summarizes this work, reviews the strengths and weaknesses of the proposed susceptibility testing standard, and identifies directions for future work.

Full text

PDF
367

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsen T. G., Widing E., Glomstein A., Gaustad P. Disseminated fungal disease resistant to fluconazole treatment in a child with leukemia. Scand J Infect Dis. 1992;24(3):391–393. doi: 10.3109/00365549209061349. [DOI] [PubMed] [Google Scholar]
  2. Akova M., Akalin H. E., Uzun O., Gür D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):598–599. doi: 10.1007/BF01967286. [DOI] [PubMed] [Google Scholar]
  3. Anaissie E. J., Bodey G. P., Rinaldi M. G. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):323–330. doi: 10.1007/BF01963467. [DOI] [PubMed] [Google Scholar]
  4. Anaissie E., Paetznick V., Bodey G. P. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob Agents Chemother. 1991 Aug;35(8):1641–1646. doi: 10.1128/aac.35.8.1641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. BAUER A. W., SHERRIS J. C. THE DETERMINATION OF SULFONAMIDE SUSCEPTIBILITY OF BACTERIA. Chemotherapy. 1964;9(1):1–19. doi: 10.1159/000220337. [DOI] [PubMed] [Google Scholar]
  6. Baker J. H., Goodpasture H. C., Kuhns H. R., Jr, Rinaldi M. G. Fungemia caused by an amphotericin B-resistant isolate of Sporothrix schenckii. Successful treatment with itraconazole. Arch Pathol Lab Med. 1989 Nov;113(11):1279–1281. [PubMed] [Google Scholar]
  7. Banerjee S. N., Emori T. G., Culver D. H., Gaynes R. P., Jarvis W. R., Horan T., Edwards J. R., Tolson J., Henderson T., Martone W. J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3. [DOI] [PubMed] [Google Scholar]
  8. Bignardi G. E., Savage M. A., Coker R., Davis S. G. Fluconazole and Candida krusei infections. J Hosp Infect. 1991 Aug;18(4):326–327. doi: 10.1016/0195-6701(91)90193-c. [DOI] [PubMed] [Google Scholar]
  9. Blanco M. T., Pérez-Giraldo C., Blanco J., Morán F. J., Hurtado C., Gómez-García A. C. In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method. Antimicrob Agents Chemother. 1992 Apr;36(4):898–901. doi: 10.1128/aac.36.4.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Block E. R., Jennings A. E., Bennett J. E. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine. Antimicrob Agents Chemother. 1973 Oct;4(4):392–395. doi: 10.1128/aac.4.4.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bodenhoff J. Resistance studies of Candida albicans, with special reference to two patients subjected to prolonged antimycotic treatment. Odontol Tidskr. 1968 Jun 28;76(3):279–294. [PubMed] [Google Scholar]
  12. Brass C., Shainhouse J. Z., Stevens D. A. Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother. 1979 Jun;15(6):763–768. doi: 10.1128/aac.15.6.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bryce E. A., Roberts F. J., Sekhon A. S., Coldman A. J. Yeast in blood cultures. Evaluation of factors influencing outcome. Diagn Microbiol Infect Dis. 1992 Mar-Apr;15(3):233–237. doi: 10.1016/0732-8893(92)90118-d. [DOI] [PubMed] [Google Scholar]
  14. Calhoun D. L., Galgiani J. N. Analysis of pH and buffer effects on flucytosine activity in broth dilution susceptibility testing of Candida albicans in two synthetic media. Antimicrob Agents Chemother. 1984 Sep;26(3):364–367. doi: 10.1128/aac.26.3.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Calhoun D. L., Roberts G. D., Galgiani J. N., Bennett J. E., Feingold D. S., Jorgensen J., Kobayashi G. S., Shadomy S. Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol. 1986 Feb;23(2):298–301. doi: 10.1128/jcm.23.2.298-301.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Calhoun D. L., Waskin H., White M. P., Bonner J. R., Mulholland J. H., Rumans L. W., Stevens D. A., Galgiani J. N. Treatment of systemic sporotrichosis with ketoconazole. Rev Infect Dis. 1991 Jan-Feb;13(1):47–51. doi: 10.1093/clinids/13.1.47. [DOI] [PubMed] [Google Scholar]
  17. Casasnovas R. O., Caillot D., Solary E., Bonotte B., Chavanet P., Bonin A., Camerlynck P., Guy H. Prophylactic fluconazole and Candida krusei infection. N Engl J Med. 1992 Mar 26;326(13):891–893. [PubMed] [Google Scholar]
  18. Case C. P., MacGowan A. P., Brown N. M., Reeves D. S., Whitehead P., Felmingham D. Prophylactic oral fluconazole and candida fungaemia. Lancet. 1991 Mar 30;337(8744):790–790. doi: 10.1016/0140-6736(91)91406-k. [DOI] [PubMed] [Google Scholar]
  19. Coleman T., Madassery J. V., Kobayashi G. S., Nahm M. H., Little J. R. New fluorescence assay for the quantitation of fungi. J Clin Microbiol. 1989 Sep;27(9):2003–2007. doi: 10.1128/jcm.27.9.2003-2007.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Conly J., Rennie R., Johnson J., Farah S., Hellman L. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis. 1992 Apr;165(4):761–764. doi: 10.1093/infdis/165.4.761. [DOI] [PubMed] [Google Scholar]
  21. Cook R. A., McIntyre K. A., Galgiani J. N. Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother. 1990 Aug;34(8):1542–1545. doi: 10.1128/aac.34.8.1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Denning D. W., Hanson L. H., Perlman A. M., Stevens D. A. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis. 1992 Jan;15(1):21–34. doi: 10.1016/0732-8893(92)90053-v. [DOI] [PubMed] [Google Scholar]
  23. Diamond R. D., Clark R. A. Damage to Aspergillus fumigatus and Rhizopus oryzae hyphae by oxidative and nonoxidative microbicidal products of human neutrophils in vitro. Infect Immun. 1982 Nov;38(2):487–495. doi: 10.1128/iai.38.2.487-495.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Diamond R. D., Krzesicki R., Epstein B., Jao W. Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis. Am J Pathol. 1978 May;91(2):313–328. [PMC free article] [PubMed] [Google Scholar]
  25. Dick J. D., Merz W. G., Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980 Jul;18(1):158–163. doi: 10.1128/aac.18.1.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Dick J. D., Rosengard B. R., Merz W. G., Stuart R. K., Hutchins G. M., Saral R. Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med. 1985 Jan;102(1):67–68. doi: 10.7326/0003-4819-102-1-67. [DOI] [PubMed] [Google Scholar]
  27. Djeu J. Y., Parapanissios A., Halkias D., Friedman H. A rapid [3H]glucose incorporation assay for determination of lymphoid cell-mediated inhibition of Candida albicans growth. J Immunol Methods. 1986 Aug 21;92(1):73–77. doi: 10.1016/0022-1759(86)90505-3. [DOI] [PubMed] [Google Scholar]
  28. Doern G. V., Tubert T. A., Chapin K., Rinaldi M. G. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. J Clin Microbiol. 1986 Oct;24(4):507–511. doi: 10.1128/jcm.24.4.507-511.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Drutz D. J., Lehrer R. I. Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci. 1978 Jul-Aug;276(1):77–92. [PubMed] [Google Scholar]
  30. Eng C., Valenstein P. Standardization of yeast inocula with an electronic impedance counter. J Clin Microbiol. 1989 Oct;27(10):2397–2399. doi: 10.1128/jcm.27.10.2397-2399.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Espinel-Ingroff A., Kerkering T. M., Goldson P. R., Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1991 Jun;29(6):1089–1094. doi: 10.1128/jcm.29.6.1089-1094.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Espinel-Ingroff A., Kerkering T. M. Spectrophotometric method of inoculum preparation for the in vitro susceptibility testing of filamentous fungi. J Clin Microbiol. 1991 Feb;29(2):393–394. doi: 10.1128/jcm.29.2.393-394.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Espinel-Ingroff A., Kish C. W., Jr, Kerkering T. M., Fromtling R. A., Bartizal K., Galgiani J. N., Villareal K., Pfaller M. A., Gerarden T., Rinaldi M. G. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 1992 Dec;30(12):3138–3145. doi: 10.1128/jcm.30.12.3138-3145.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Espinel-Ingroff A., Shadomy S., Gebhart R. J. In vitro studies with R 51,211 (itraconazole). Antimicrob Agents Chemother. 1984 Jul;26(1):5–9. doi: 10.1128/aac.26.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Fan-Havard P., Capano D., Smith S. M., Mangia A., Eng R. H. Development of resistance in candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991 Nov;35(11):2302–2305. doi: 10.1128/aac.35.11.2302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Fisher M. A., Shen S. H., Haddad J., Tarry W. F. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei. Antimicrob Agents Chemother. 1989 Sep;33(9):1443–1446. doi: 10.1128/aac.33.9.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Fromtling R. A., Galgiani J. N., Pfaller M. A., Espinel-Ingroff A., Bartizal K. F., Bartlett M. S., Body B. A., Frey C., Hall G., Roberts G. D. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob Agents Chemother. 1993 Jan;37(1):39–45. doi: 10.1128/aac.37.1.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Galgiani J. N. Antifungal susceptibility tests. Antimicrob Agents Chemother. 1987 Dec;31(12):1867–1870. doi: 10.1128/aac.31.12.1867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Galgiani J. N., Reiser J., Brass C., Espinel-Ingroff A., Gordon M. A., Kerkering T. M. Comparison of relative susceptibilities of Candida species to three antifungal agents as determined by unstandardized methods. Antimicrob Agents Chemother. 1987 Sep;31(9):1343–1347. doi: 10.1128/aac.31.9.1343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Galgiani J. N., Rinaldi M. G., Polak A. M., Pfaller M. A. Standardization of antifungal susceptibility testing. J Med Vet Mycol. 1992;30 (Suppl 1):213–224. doi: 10.1080/02681219280000911. [DOI] [PubMed] [Google Scholar]
  41. Galgiani J. N., Stevens D. A. Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother. 1976 Oct;10(4):721–728. doi: 10.1128/aac.10.4.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Galgiani J. N., Stevens D. A., Graybill J. R., Dismukes W. E., Cloud G. A. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. Am J Med. 1988 Mar;84(3 Pt 2):603–610. doi: 10.1016/0002-9343(88)90143-x. [DOI] [PubMed] [Google Scholar]
  43. Galgiani J. N., Sun S. H., Clemons K. V., Stevens D. A. Activity of cilofungin against Coccidioides immitis: differential in vitro effects on mycelia and spherules correlated with in vivo studies. J Infect Dis. 1990 Oct;162(4):944–948. doi: 10.1093/infdis/162.4.944. [DOI] [PubMed] [Google Scholar]
  44. Galgiant J. N., Stevens D. A. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother. 1978 Feb;13(2):249–254. doi: 10.1128/aac.13.2.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ghannoum M. A., Ibrahim A. S., Fu Y., Shafiq M. C., Edwards J. E., Jr, Criddle R. S. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol. 1992 Nov;30(11):2881–2886. doi: 10.1128/jcm.30.11.2881-2886.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Goodman J. L., Winston D. J., Greenfield R. A., Chandrasekar P. H., Fox B., Kaizer H., Shadduck R. K., Shea T. C., Stiff P., Friedman D. J. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992 Mar 26;326(13):845–851. doi: 10.1056/NEJM199203263261301. [DOI] [PubMed] [Google Scholar]
  47. Gordon M. A., Lapa E. W., Passero P. G. Improved method for azole antifungal susceptibility testing. J Clin Microbiol. 1988 Sep;26(9):1874–1877. doi: 10.1128/jcm.26.9.1874-1877.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Grendahl J. G., Sung J. P. Quantitation of imidazoles by agar-disk diffusion. Antimicrob Agents Chemother. 1978 Sep;14(3):509–513. doi: 10.1128/aac.14.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Guinet R., Chanas J., Goullier A., Bonnefoy G., Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol. 1983 Aug;18(2):443–444. doi: 10.1128/jcm.18.2.443-444.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Guinet R., Nerson D., de Closets F., Dupouy-Camet J., Kures L., Marjollet M., Poirot J. L., Ros A., Texier-Maugein J., Volle P. J. Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J Clin Microbiol. 1988 Nov;26(11):2307–2312. doi: 10.1128/jcm.26.11.2307-2312.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Hector R. F., Zimmer B. L., Pappagianis D. Microtiter method for MIC testing with spherule-endospore-phase Coccidioides immitis. J Clin Microbiol. 1988 Dec;26(12):2667–2668. doi: 10.1128/jcm.26.12.2667-2668.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Hitchcock C. A., Russell N. J., Barrett-Bee K. J. Sterols in Candida albicans mutants resistant to polyene or azole antifungals, and of a double mutant C. albicans 6.4. Crit Rev Microbiol. 1987;15(1):111–115. doi: 10.3109/10408418709104454. [DOI] [PubMed] [Google Scholar]
  53. Hoeprich P. D., Finn P. D. Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis. 1972 Oct;126(4):353–361. doi: 10.1093/infdis/126.4.353. [DOI] [PubMed] [Google Scholar]
  54. Hoeprich P. D., Huston A. C. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. J Infect Dis. 1976 Oct;134(4):336–341. doi: 10.1093/infdis/134.4.336. [DOI] [PubMed] [Google Scholar]
  55. Hoeprich P. D., Huston A. C. Stability of four antifungal antimicrobics in vitro. J Infect Dis. 1978 Jan;137(1):87–93. doi: 10.1093/infdis/137.1.87. [DOI] [PubMed] [Google Scholar]
  56. Holt R. J., Azmi A. Miconazole-resistant Candida. Lancet. 1978 Jan 7;1(8054):50–51. doi: 10.1016/s0140-6736(78)90403-8. [DOI] [PubMed] [Google Scholar]
  57. Horsburgh C. R., Jr, Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 1983 Jan 24;74(1B):23–29. doi: 10.1016/0002-9343(83)90511-9. [DOI] [PubMed] [Google Scholar]
  58. Hughes C. E., Beggs W. H. Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. J Antimicrob Chemother. 1987 Feb;19(2):171–174. doi: 10.1093/jac/19.2.171. [DOI] [PubMed] [Google Scholar]
  59. Hughes C. E., Bennett R. L., Tuna I. C., Beggs W. H. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob Agents Chemother. 1988 Feb;32(2):209–212. doi: 10.1128/aac.32.2.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Huppert M., Pappagianis D., Sun S. H., Gleason-Jordan I., Collins M. S., Vukovich K. R. Effect of amphotericin B and rifampin against Coccidioides immitis in vitro and in vivo. Antimicrob Agents Chemother. 1976 Mar;9(3):406–413. doi: 10.1128/aac.9.3.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Johnson E. M., Richardson M. D., Warnock D. W. In-vitro resistance to imidazole antifungals in Candida albicans. J Antimicrob Chemother. 1984 Jun;13(6):547–558. doi: 10.1093/jac/13.6.547. [DOI] [PubMed] [Google Scholar]
  62. Kelly S. L., Rowe J., Watson P. F. Molecular genetic studies on the mode of action of azole antifungal agents. Biochem Soc Trans. 1991 Aug;19(3):796–798. doi: 10.1042/bst0190796. [DOI] [PubMed] [Google Scholar]
  63. Kerridge D., Fasoli M., Wayman F. J. Drug resistance in Candida albicans and Candida glabrata. Ann N Y Acad Sci. 1988;544:245–259. doi: 10.1111/j.1749-6632.1988.tb40410.x. [DOI] [PubMed] [Google Scholar]
  64. LAMPEN J. O., ARNOW P. M., SAFFERMAN R. S. Mechanism of protection by sterols against polyene antibiotics. J Bacteriol. 1960 Aug;80:200–206. doi: 10.1128/jb.80.2.200-206.1960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Levitz S. M., Diamond R. D. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis. 1985 Nov;152(5):938–945. doi: 10.1093/infdis/152.5.938. [DOI] [PubMed] [Google Scholar]
  66. MacKerrow S. D., Merry J. M., Hoeprich P. D. Effect of buffers on testing of Candida species susceptibility to flucytosine. J Clin Microbiol. 1987 May;25(5):885–888. doi: 10.1128/jcm.25.5.885-888.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. McIlroy M. A. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhlitis. J Infect Dis. 1991 Feb;163(2):420–421. doi: 10.1093/infdis/163.2.420. [DOI] [PubMed] [Google Scholar]
  68. McIntyre K. A., Galgiani J. N. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother. 1989 Jul;33(7):1095–1100. doi: 10.1128/aac.33.7.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. McIntyre K. A., Galgiani J. N. pH and other effects on the antifungal activity of cilofungin (LY121019). Antimicrob Agents Chemother. 1989 May;33(5):731–735. doi: 10.1128/aac.33.5.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Merz W. G. Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol. 1984 Dec;20(6):1194–1195. doi: 10.1128/jcm.20.6.1194-1195.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Merz W. G., Fay D., Thumar B., Dixon D. Susceptibility testing of filamentous fungi to amphotericin B by a rapid radiometric method. J Clin Microbiol. 1984 Jan;19(1):54–56. doi: 10.1128/jcm.19.1.54-56.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Merz W. G., Sandford G. R. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol. 1979 Jun;9(6):677–680. doi: 10.1128/jcm.9.6.677-680.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Minagawa H., Kitaura K., Nakamizo N. Effects of pH on the activity of ketoconazole against Candida albicans. Antimicrob Agents Chemother. 1983 Jan;23(1):105–107. doi: 10.1128/aac.23.1.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. O'Day D. M., Ray W. A., Robinson R. D., Head W. S. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin. Invest Ophthalmol Vis Sci. 1987 Mar;28(3):596–603. [PubMed] [Google Scholar]
  75. Odds F. C., Abbott A. B., Pye G., Troke P. F. Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. J Med Vet Mycol. 1986 Aug;24(4):305–311. doi: 10.1080/02681218680000461. [DOI] [PubMed] [Google Scholar]
  76. Odds F. C., Abbott A. B. Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro. J Antimicrob Chemother. 1984 Jan;13(1):31–43. doi: 10.1093/jac/13.1.31. [DOI] [PubMed] [Google Scholar]
  77. Odds F. C. Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob Agents Chemother. 1992 Aug;36(8):1727–1737. doi: 10.1128/aac.36.8.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Odds F. C. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982 Nov;22(5):763–770. doi: 10.1128/aac.22.5.763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Odds F. C. Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother. 1980 Nov;6(6):749–761. doi: 10.1093/jac/6.6.749. [DOI] [PubMed] [Google Scholar]
  80. Odds F. C. Quantitative microculture system with standardized inocula for strain typing, susceptibility testing, and other physiologic measurements with Candida albicans and other yeasts. J Clin Microbiol. 1991 Dec;29(12):2735–2740. doi: 10.1128/jcm.29.12.2735-2740.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Oh K., Matsuoka H., Sumita O., Takatori K., Kurata H. Evaluation of antifungal activity of antimycotics by automatic analyzing system. Mycopathologia. 1992 May;118(2):71–81. doi: 10.1007/BF00442534. [DOI] [PubMed] [Google Scholar]
  82. Pappagianis D., Collins M. S., Hector R., Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979 Aug;16(2):123–126. doi: 10.1128/aac.16.2.123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Perfect J. R., Durack D. T. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother. 1985 Dec;28(6):751–755. doi: 10.1128/aac.28.6.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Perfect J. R., Savani D. V., Durack D. T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother. 1986 Apr;29(4):579–583. doi: 10.1128/aac.29.4.579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Persons D. A., Laughlin M., Tanner D., Perfect J., Gockerman J. P., Hathorn J. W. Fluconazole and Candida krusei fungemia. N Engl J Med. 1991 Oct 31;325(18):1315–1315. [PubMed] [Google Scholar]
  86. Pfaller M. A., Burmeister L., Bartlett M. S., Rinaldi M. G. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol. 1988 Aug;26(8):1437–1441. doi: 10.1128/jcm.26.8.1437-1441.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Pfaller M. A., Rinaldi M. G., Galgiani J. N., Bartlett M. S., Body B. A., Espinel-Ingroff A., Fromtling R. A., Hall G. S., Hughes C. E., Odds F. C. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother. 1990 Sep;34(9):1648–1654. doi: 10.1128/aac.34.9.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Plempel M., Regel E., Büchel K. H. Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneimittelforschung. 1983;33(4):517–524. [PubMed] [Google Scholar]
  89. Plempel M. Versuche zur Korrelation von In-vitro- und In-vivo-Wirkungen bei Azol-Antimykotika. Mykosen. 1984 Jan;27(1):7–13. [PubMed] [Google Scholar]
  90. Polak A., Odds F. C., Lüdin E., Scholer H. J. Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model. Chemotherapy. 1985;31(5):395–404. doi: 10.1159/000238365. [DOI] [PubMed] [Google Scholar]
  91. Polak A., Scholer H. J. Fungistatic activity, uptake and incorporation of 5-fluorocytosine in Candida albicans, as influenced by pyrimidines and purines. I. Reversal experiments. Pathol Microbiol (Basel) 1973;39(2):148–159. doi: 10.1159/000162642. [DOI] [PubMed] [Google Scholar]
  92. Powderly W. G., Kobayashi G. S., Herzig G. P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988 May;84(5):826–832. doi: 10.1016/0002-9343(88)90059-9. [DOI] [PubMed] [Google Scholar]
  93. Radetsky M., Wheeler R. C., Roe M. H., Todd J. K. Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome. J Clin Microbiol. 1986 Oct;24(4):600–606. doi: 10.1128/jcm.24.4.600-606.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Rex J. H., Bennett J. E., Gallin J. I., Malech H. L., Melnick D. A. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis. 1990 Aug;162(2):523–528. doi: 10.1093/infdis/162.2.523. [DOI] [PubMed] [Google Scholar]
  95. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Ryley J. F., Wilson R. G., Barrett-Bee K. J. Azole resistance in Candida albicans. Sabouraudia. 1984;22(1):53–63. [PubMed] [Google Scholar]
  97. Røder B. L., Sonnenschein C., Hartzen S. H. Failure of fluconazole therapy in Candida krusei fungemia. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):173–173. doi: 10.1007/BF01964453. [DOI] [PubMed] [Google Scholar]
  98. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Saubolle M. A., Hoeprich P. D. Disk agar diffusion susceptibility testing of yeasts. Antimicrob Agents Chemother. 1978 Oct;14(4):517–530. doi: 10.1128/aac.14.4.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Schuler U., Ehninger G. Prophylactic fluconazole and Candida krusei infection. N Engl J Med. 1992 Mar 26;326(13):892–893. [PubMed] [Google Scholar]
  101. Seidenfeld S. M., Cooper B. H., Smith J. W., Mackowiak P. A. Effect of temperature on the susceptibility of Sporothrix schenckii to amphotericin B. J Infect Dis. 1982 Nov;146(5):711–711. doi: 10.1093/infdis/146.5.711. [DOI] [PubMed] [Google Scholar]
  102. Shadomy S., White S. C., Yu H. P., Dismukes W. E. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis. 1985 Dec;152(6):1249–1256. doi: 10.1093/infdis/152.6.1249. [DOI] [PubMed] [Google Scholar]
  103. Shawar R., Paetznick V., Witte Z., Ensign L. G., Anaissie E., LaRocco M. Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans. J Clin Microbiol. 1992 Aug;30(8):1976–1981. doi: 10.1128/jcm.30.8.1976-1981.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Smith K. J., Warnock D. W., Kennedy C. T., Johnson E. M., Hopwood V., Van Cutsem J., Vanden Bossche H. Azole resistance in Candida albicans. J Med Vet Mycol. 1986 Apr;24(2):133–144. [PubMed] [Google Scholar]
  105. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis. 1983 Jun;147(6):1070–1077. doi: 10.1093/infdis/147.6.1070. [DOI] [PubMed] [Google Scholar]
  106. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother. 1982 Sep;22(3):482–487. doi: 10.1128/aac.22.3.482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Tam J. Y., Blume K. G., Prober C. G. Prophylactic fluconazole and Candida krusei infections. N Engl J Med. 1992 Mar 26;326(13):891–893. doi: 10.1056/NEJM199203263261312. [DOI] [PubMed] [Google Scholar]
  108. Taylor P. C., Schoenknecht F. D., Sherris J. C., Linner E. C. Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob Agents Chemother. 1983 Jan;23(1):142–150. doi: 10.1128/aac.23.1.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Tellier R., Krajden M., Grigoriew G. A., Campbell I. Innovative endpoint determination system for antifungal susceptibility testing of yeasts. Antimicrob Agents Chemother. 1992 Aug;36(8):1619–1625. doi: 10.1128/aac.36.8.1619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Utz C. J., Shadomy S. Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing. J Infect Dis. 1977 Jun;135(6):970–974. doi: 10.1093/infdis/135.6.970. [DOI] [PubMed] [Google Scholar]
  111. Van der Auwera P., Ceuppens A. M., Heymans C., Meunier F. In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations. Antimicrob Agents Chemother. 1986 Jun;29(6):997–1004. doi: 10.1128/aac.29.6.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Velez J. D., Allendoerfer R., Luther M., Rinaldi M. G., Graybill J. R. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis. 1993 Aug;168(2):508–510. doi: 10.1093/infdis/168.2.508. [DOI] [PubMed] [Google Scholar]
  113. Walsh T. J., Melcher G. P., Rinaldi M. G., Lecciones J., McGough D. A., Kelly P., Lee J., Callender D., Rubin M., Pizzo P. A. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990 Jul;28(7):1616–1622. doi: 10.1128/jcm.28.7.1616-1622.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Warnock D. W., Burke J., Cope N. J., Johnson E. M., von Fraunhofer N. A., Williams E. W. Fluconazole resistance in Candida glabrata. Lancet. 1988 Dec 3;2(8623):1310–1310. doi: 10.1016/s0140-6736(88)92919-4. [DOI] [PubMed] [Google Scholar]
  115. Warnock D. W., Johnson E. M., Richardson M. D., Vickers C. F. Modified response to ketoconazole of Candida albicans from a treatment failure. Lancet. 1983 Mar 19;1(8325):642–643. doi: 10.1016/s0140-6736(83)91809-3. [DOI] [PubMed] [Google Scholar]
  116. Willocks L., Leen C. L., Brettle R. P., Urquhart D., Russell T. B., Milne L. J. Fluconazole resistance in AIDS patients. J Antimicrob Chemother. 1991 Dec;28(6):937–939. doi: 10.1093/jac/28.6.937. [DOI] [PubMed] [Google Scholar]
  117. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991 Oct 31;325(18):1274–1277. doi: 10.1056/NEJM199110313251803. [DOI] [PubMed] [Google Scholar]
  118. Yamada S., Cao J., Sumita O., Kurasawa K., Kurata H., Oh K., Matsuoka H. Automatic antifungal activity analyzing system on the basis of dynamic growth process of a single hypha. Mycopathologia. 1992 May;118(2):65–69. doi: 10.1007/BF00442533. [DOI] [PubMed] [Google Scholar]
  119. vanden Bossche H., Marichal P., Odds F. C., Le Jeune L., Coene M. C. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother. 1992 Dec;36(12):2602–2610. doi: 10.1128/aac.36.12.2602. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Microbiology Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES